CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

The Importance of Technology in Multinational Clinical Research

The Importance of Technology in...

Managing Data in Digital Clinical Trials

Managing Data in Digital Clinical...

Israel-Based Clearmind Medicine Offers First Clinical Center for Alcohol Use Disorder Trial

Israel-Based Clearmind Medicine...

Adagene Offers Clinical Trial Collaboration to Evaluate Roche's Standard-of-Care for First-Line Advanced Liver Cancer

Adagene Offers Clinical Trial...

Outsourcing the Potential Laboratory Services To Ensure Maximum Efficacy of Trials

Outsourcing the Potential Laboratory...

Accessing Sensitive Research Data Via European Genome-Phenome Archive(EGA)

Accessing Sensitive Research Data Via...

Boosting Clinical Cooperation for Improved Efficacy of Clinical Trials

Boosting Clinical Cooperation for...

Clinical Trials Climate in EU to Upsurge in the Future

Clinical Trials Climate in EU to...

The Importance of Technology in Multinational Clinical Research

The Importance of Technology in...

Managing Data in Digital Clinical Trials

Managing Data in Digital Clinical...

Israel-Based Clearmind Medicine Offers First Clinical Center for Alcohol Use Disorder Trial

Israel-Based Clearmind Medicine...

Adagene Offers Clinical Trial Collaboration to Evaluate Roche's Standard-of-Care for First-Line Advanced Liver Cancer

Adagene Offers Clinical Trial...

Outsourcing the Potential Laboratory Services To Ensure Maximum Efficacy of Trials

Outsourcing the Potential Laboratory...

Accessing Sensitive Research Data Via European Genome-Phenome Archive(EGA)

Accessing Sensitive Research Data Via...

Boosting Clinical Cooperation for Improved Efficacy of Clinical Trials

Boosting Clinical Cooperation for...

Clinical Trials Climate in EU to Upsurge in the Future

Clinical Trials Climate in EU to...

China biopharma sector focuses on innovation.

Life Sciences Review | Wednesday, December 29, 2021
Tweet

Summary: China’s biopharma sector has seen a major shift from formerly generics-focused play to the one that encourages and concentrates on innovation, along with profound implications for patients and industry peers.


FREMONT, CA:A momentous shift from a formerly generics focused play into one that encourages innovation, along with profound implications for patients and industry peers has been experienced by China's biopharmaceutical ecosystem.Highlighted by substantial value creation on global capital markets, innovation in Chinese biopharma is close to becoming a notable story. The market value of publicly listed biopharma innovation players from China such as the Nasdaq, Shangai Stock Exchange Science and Technology Innovation Board (STAR) and Hong Kong Stock Exchange (HKEX) reached 380 billion dollars in July 2021, from 3 billion dollars in 2016.


Of the total, the China originated biotechnology companies independently have accounted for 180 billion dollars. Additionally, with 23 IPOs in the last year alone, the public debuts for Chinese players have also revived. Therefore, as seven out of the world's top ten largest biopharma IPOs have originated from China from 2018 to 2021, the Chinese biotechs are currently leading on IPO fundraising. 


Additionally, the rising demand for new drug discoveries with the potential to satisfy the domestic market needs and beyond has helped China increase its share of the global pipeline from 4.1 percent in 2015 to 13.9 percent in 2020.


Moreover, in enabling Chinese biopharma to emerge on the global innovation stage, regulatory reforms, the emergence of bioclusters in areas such as the city of Suzhou, the opening of China's capital markets, and the talent returning from overseas have played a vital role. McKinsey maintains the China Drug Innovation Index (CDII) in order to comprehend how China's biopharma innovation ecosystem is evolving and to obtain a more subtle sense regarding its growth drivers. This survey that was first launched in 2016 questions the industry experts to measure five dimensions that support healthy biopharma innovation such as policy environment which is split between regulatory reforms and market access policies, funding, research and development, local innovation output, and integration with global markets.


Weekly Brief

loading

  • Top 10 Clinical Trial Services Companies - 2022
  • Top 10 Emerging Clinical Trial Management Companies - 2022
  • Top 10 Clinical Trial Management System Companies - 2022
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue

Read Also

The Role of AI in Accurate Medical Writing

Patrik Renblad to Join Cantargia as Chief Financial Officer

Overview of the Life Sciences BPO Market

Dr. Zamaneh Mikhak Joins TFF Pharmaceutical as the New Chief Medical Officer

The Significance of AI in Medical Writing

The Importance of Technology in Multinational Clinical Research

Hepion Pharmaceuticals to Get a Total of $ 3.2 Million in Non-Dilutive Financing

Benefits that Medical Writing Offers

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/china-biopharma-sector-focuses-on-innovation-nwid-674.html